Despite the optimal use of anti-anginal medications and coronary revascularization, a large number of patients with CAD suffer from severe symptoms with disabling angina and heart failure. It is estimated that 300,000 to 900,000 patients in the United States alsone have exhausted conventional medical therapies and continue to experience angina, with 100,000 to 200,000 new cases per year. The development of new therapies for this patient population therefore represents a suitable therapeutic target.
Primary Objective- To determine the effect of direct endomyocardial injection of autologous BM cells on LVF in patients with "no option" chronic ischaemic HF.
Secondary Objective- To assess the effect of symptoms, exercise capacity, infarct and peri-infarct region function and perfusion, comined clinical endpoint of heart failure hospitalization, myocardial infarction and cardiovascular death, and the safety and efficacy of the endomyocardial injection technique.